Controversies in postpartum contraception: When is it safe to start oral contraceptives after childbirth?

Thrombosis Research

Volumn 127, Issue SUPPL. 3, 2011, Pages

  Jackson, Emily ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Breastfeeding; Contraception; Postpartum contraception; Venous thromboembolism

Indexed keywords

ANTICOAGULANT PROTEIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PROCOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST FEEDING; CARDIOVASCULAR RISK; CESAREAN SECTION; CHILDBIRTH; CLINICAL TRIAL; CONTRACEPTION; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; FIBRINOGEN BLOOD LEVEL; GROWTH CURVE; HEALTH; HIGH RISK POPULATION; HORMONAL CONTRACEPTION; HUMAN; INFECTION; LACTATION; LACTATIONAL AMENORRHEA METHOD; LOW DRUG DOSE; LUNG EMBOLISM; MENSTRUATION; MILK PRODUCTION; OBESITY; ORAL CONTRACEPTION; PRACTICE GUIDELINE; PREECLAMPSIA; PRIORITY JOURNAL; PUERPERIUM; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW; THROMBOPHILIA; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

BREAST FEEDING; CONTRACEPTION; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; POSTPARTUM PERIOD; VENOUS THROMBOEMBOLISM;

EID: 79251480406     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(11)70010-X     Document Type: Article

References (59)

1. AO Tsui, JN Wasserheit, J Haaga, the National Research Council (US) Panel on Reproductive Health Reproductive health in developing countries: expanding dimensions, building solutions 1997 National Academy Press Washington
2. S Grisaru-Granovsky, E Gordon, Z Haklai, A Samueloff, MM Schimmel Effect of interpregnancy interval on adverse perinatal outcomes - a national study Contraception 80 2009 512 518
3. A Conde-Agudelo, JM Belizan Maternal morbidity and mortality associated with interpregnancy interval: a cross-sectional study BMJ 321 2000 1255 1259
4. V Setty-Venugopal, UD Upadhyay Effects of birth spacing: three to five saves lives Population Rep Ser L 13 2002 1 23
5. World Health Organziation Report of a WHO technical consultation on birth spacing 2005 WHO Press Geneva
6. PC Erwin To use or not use combined hormonal oral contraceptives during lactation Fam Plann Perspect 26 1 1994 26 31
7. United Nations, Population Division, Department of Economic and Social Affairs World Contraceptive Use 2009 2009 United Nations New York
8. th edition 2007 Ardent Media Inc. New York 193 270
9. World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP), INFO Project Family planning: a global handbook for providers 2007 CCP and WHO Baltimore and Geneva
10. th edition 2007 Ardent Media Inc. New York 181 191
11. S Diaz, HB Croxatto Contraception in lactating women Curr Opin Obstet Gynecol 5 1993 815 822
12. th edition 2007 Ardent Media Inc. New York 403 431
13. LD Halderman, AL Nelson Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns Am J Obstet Gynecol 186 2002 1250 1256
14. Truitt St, Fraser AB, Gallo MF, Lopez LM, Grimes DA, Schulz KF. Combined hormonal versus nonhormonal vs progestin-only contraception in lactation. Cochrane Database Syst Rev 2003; Issue 2, Article No CD003988.
15. N Kapp, K Curtis Combined oral contraceptive use among breastfeeding women: a systematic review Contraception 82 2010 10 16
16. N Kapp, K Curtis, K Nanda Progestogen-only contraceptive use among breastfeeding women: a systematic review Contraception 82 2010 17 37
17. World Health Organization Technical consultation on hormonal contraceptive use during lactation and effects on the newborn: summary report 2010 WHO Press Geneva
18. th edition 2010 WHO Press Geneva
19. National Institute for Health and Clinical Excellence UK medical eligibility criteria for contraceptive use http://www.cks.nhs.uk/contraception/ management/detailed-answers/uk-medical-eligibility-criteria [Accessed September 1, 2010].
20. Department for Health and Human Services, Centers for Disease Control and Prevention US medical eligibility for contraceptive use, 2010 MMWR 59 2010 1 86
21. S Ip, M Chung, G Raman, TA Trikalinos, J Lau A summary of the Agency for Healthcare Research and Quality's evidence report on breastfeeding in developed countries Breastfeed Med 4 Suppl 1 2009 S17 S30
22. B Horta, R Bahl, J Martines, C Victoria Evidence of the long-term effects of breastfeeding: systematic reviews and meta-analysis 2007 WHO Press Geneva
23. LM Gartner, J Morton, RA Lawrence, AJ Naylor, D O'Hare, RJ Schanler American Academy of Pediatrics Section on Breastfeeding Breastfeeding and the use of human milk Pediatrics 115 2005 496 506
24. SG Folger, KM Curtis, NK Tepper, ME Gaffield, PA Marchbanks Guidance on medical eligibility criteria for contraceptive use: identification of research gaps Contraception 82 2010 113 118
25. J Trussell, EB Schwarz, K Guthrie Research priorities for preventing unintended pregnancy: moving beyond emergency contraceptive pills Perspect Sex Reprod Health 42 l 2010 8 9
26. C Moran, LS Alcazar, S Carranza-Lira, G Merino, R Ballon Recovery of ovarian function after childbirth, lactation and sexual activity with relation to age of women Contraception 50 1994 401 407
27. KA Bremme Haemostatic changes in pregnancy Best Pract Res Clin Haemtol 16 2 2003 153 168
28. H Maybury, J Waugh, A Gornall, S Pavord There is a return to nonpregnant coagulation parameters after four not six weeks postpartum following spontaneous vaginal delivery Obstetric Medicine 1 2008 92
29. P Saha, D Stott, R Atalla Haemostatic changes in the puerperium '6 weeks postpartum' (HIP Study) - implication for maternal thromboembolism BJOG 116 2009 1602 1612
30. P Clark Changes in hemostasis variables during pregnancy Semin Vasc Med 3 l 2003 13 24
31. N Macklon, I Greer Deep venous flow in the leg in pregnancy and puerperium Contemp Rev Obstet Gynaecol 9 1997 93 98
32. N Macklon, I Greer, A Bowman An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy BJOG 104 1997 191 197
33. I Greer Thrombosis in pregnancy: maternal and fetal issues Lancet 353 9160 1999 1258 1266
34. JA Heit, CE Kobbervig, AH James, TM Petterson, K Bailey, LJ Melton Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study Ann Intern Med 143 10 2005 697 706
35. ER Pomp, AM Lenselink, FR Rosendaal, CJ Doggen Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study J Thromb Haemost 6 4 2008 632 637
36. HS Ros, P Lichtenstein, R Bellocco, G Petersson, S Cnattingius Increased risks of circulatory diseases in late pregnancy and puerperium Epidemiology 12 4 2001 456 460
37. MD McColl, JE Ramsay, RC Tait, ID Walker, F McCall, JA Conkie Risk factors for pregnancy associated venous thromboembolism Thromb Haemost 78 1997 1183 1188
38. A James, MG Jamison, LR Brancazio, ER Myers Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors and mortality Am J Obstet Gynecol 194 5 2006 1311 1315
39. AF Jacobsen, FE Skjeldestad, PM Sandset Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study J Thromb Haemost 6 6 2008 905 912
40. EL Simpson, RA Lawrenson, AL Nightingale, RD Farmer Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database BJOG 108 l 2001 56 60
41. A James Prevention and management of venous thromboembolism in pregnancy Am Journal Med 120 2007 S26 S34
42. PG Lindqvist, B Dahlback, K Marsal Thrombotic risk during pregnancy: A population study Obstet Gynecol 94 1999 595 599
43. TB Larsen, HT Sorensen, M Gislum, SP Johnsen Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population based nested case-control study Thromb Res 120 4 2007 505 509
44. P Brill-Edwards, J Ginsberg, M Gent, J Hirsh, R Burrows, C Kearon Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of clot in this pregnancy study group N Engl J Med 343 2000 1439 1444
45. I Pabinger, B Schneider Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hämostaseforschung (GTH) Study Group on Natural Inhibitors Arterioscler Thromb Vasc Biol 16 1996 742 748
46. O Lidegaard, E Lokkegaard, AL Svendsen, C Agger Hormonal contraception and risk of venous thromboembolism: national follow-up study BMJ 339 b2890 2009
47. A van Hylckama Vlieg, FM Helmerhorst, JP Vandenbrouke, CJ Doggen, FR Rosendaal The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study BMJ 339 b2921 2009
48. JP Vandenbrouke, J Rosing, KWM Bloemenkamp, S Middeldorp, FM Helmerhorst, BN Bouma Oral contraceptives and the risk of venous thrombosis N Engl J Med 344 20 2001 1527 1535
49. WO Spitzer Third generation oral contraceptives and risk of venous thromboembolic disorders: and international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women BMJ Clin Res 312 7023 1996 83 88
50. M Abdollahi, M Cushman, FR Rosendaal Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use Thromb Haemost 89 2003 493 498
51. SM Middeldorp Effects on coagulation of levonorgestrel- and desogestrelcontaining low dose oral contraceptives: a cross-over study Thromb Haemostat 84 1 2000 4 8
52. G Tans A rondomized cross-over study on the effects of levonorgestreland desogestrel-containing oral contraceptives on the anticoagulant pathways Thromb Haemost 84 1 2000 15 21
53. J Rosing Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study Lancet 354 9195 1999 2036 2040
54. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease Lancet 346 8990 1995 1582 1588
55. S Jick, J Kaye, S Russman, H Jick Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol Contraception 73 3 2006 223 228
56. J Johnson, J Lowell, G Badger, J Rosing, S Tchaikovski, M Cushman Effects of oral and transdermal hormonal contraception on vascular risk markers: a radnomized controlled trial Obstet Gynecol 111 2 2008 278 284
57. H van Vliet Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor J Thromb Haemost 6 2 2008 346 351
58. M Alhenc-Gelas Impact of progestogens on activated protein C (APC) resistance among users of oral contraceptives J Thromb Haemostat 2 9 2004 1594 1600
59. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter case-control study Contraception 57 5 1998 315 324